# TROP2

Source: https://nuclide.cc/targets/trop2/  
Nuclide record `trop2` (Target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.

## Summary

Trophoblast cell-surface antigen 2 is a transmembrane glycoprotein overexpressed in most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) with low normal-tissue expression. It is not an oncogenic driver; it is a delivery address. Three TROP2 ADCs are approved or in registration (sacituzumab govitecan, datopotamab deruxtecan, sacituzumab tirumotecan) and a TROP2 PET tracer is in development to select patients.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target; pet-target
- Symbol: TACSTD2
- Class: surface-antigen
- Biology: Regulates calcium signalling and cell adhesion; overexpression correlates with poor prognosis. Expression is heterogeneous within tumours, which limits the value of IHC selection. Internalises on antibody binding and traffics to lysosomes, which is what makes it a good ADC target.
- Where found: Triple-negative breast cancer (~80-90% express); HR+ breast cancer; NSCLC; Urothelial carcinoma; Gastric, pancreatic, endometrial cancers

## Sources

- UniProt P09758: TACSTD2 (TROP2): https://www.uniprot.org/uniprotkb/P09758/entry

## Connected records

- technologies: [Immuno-PET](https://nuclide.cc/technologies/immuno-pet/), [TROP2 PET](https://nuclide.cc/technologies/trop2-pet/)
- institutions: [Fudan University Shanghai Cancer Center](https://nuclide.cc/institutions/fuscc/)
- terms: [Antigen](https://nuclide.cc/terms/antigen/)
- ideas: [Alpha radioligands after ADC failure](https://nuclide.cc/ideas/idea-alpha-after-adc/), [TROP2 PET to choose and sequence TROP2 ADCs](https://nuclide.cc/ideas/idea-trop2-pet-selection/)
- people: [Shaoli Song](https://nuclide.cc/people/song-shaoli/)
- indications: [Triple-negative breast cancer](https://nuclide.cc/indications/breast-triple-negative/)
- opportunities: [TROP2 imaging where no tissue test is required](https://nuclide.cc/opportunities/opp-trop2-imaging-heterogeneity/)
- targets: [5T4 (trophoblast glycoprotein)](https://nuclide.cc/targets/tpbg-5t4/)

---
JSON: https://nuclide.cc/api/v1/entities/trop2.json